NK can kill tumor cells directly (releasing soluble granules, expressing apoptosis-inducing ligands, ADCC function) or indirectly (secreting a variety of cytokines, chemotactic molecules and growth factors to activate other immune cells). , which is expected to treat a variety of hematological tumors and solid tumors.

iPSC-NK products have the advantages of large batch output, stable quality, superior tumor killing performance, resistance to cryopreservation and recovery, and easy multi-element gene modification.

At present, the company's first iPSC-iNK has obtained clinical implicit approval from CDE, and is the first clinically approved iNK in China. In the future, Nuwacell Biotechnologies Co., Ltd. will continue to develop iNK products for different indications.